France · Delayed Price · Currency is EUR Novacyt Earnings Call Transcripts
Fiscal Year 2026
-
Acquisition of Southern Cross Diagnostics accelerates growth, profitability, and product expansion, with immediate accretive impact and direct access to key customers in Australia and New Zealand. Capital raise was oversubscribed, strengthening the balance sheet and supporting future product launches and partnerships.
Fiscal Year 2025
-
Revenue grew 4% year-on-year to GBP 20 million, with strong gross margins and reduced losses. Strategic R&D investment, new product launches, and the Southern Cross acquisition are driving growth, with double-digit revenue growth targeted for 2026.
Fiscal Year 2024
-
Major operational consolidation and cost reductions delivered GBP 8 million in savings, with strong growth in reproductive healthcare and a stabilized high-margin research segment. Cash reserves remain robust, supporting increased R&D investment and a confident outlook for profitability.
-
Double-digit growth in core reproductive health products and a GBP 7 million cash boost from DHSC dispute resolution have strengthened the financial position. Integration of Yourgene is ahead of schedule, with cost savings and R&D investment supporting future growth.